Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot retreatment study of pegylated interferon, ribavirin, and amantadine in chronic hepatitis C
NL-OMON27702Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2002
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2b, ribavirin, amantadine and interferon alfa in hepatitis C virus infection (4 arms), sponsored by Merck & Co. Primary endpoint: Predictive value of initial viral load decline for sustained virological response. Started Jan 2002; status: active, not recruiting.
02
Drugs
peginterferon alfa-2bribavirinamantadineinterferon alfa
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON27702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27702.